In this phase 2, randomized trial in early #Alzheimers disease, the #TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes. #microglia #AD
https://www.nature.com/articles/s41591-026-04273-1